Cardiac Dysfunction and Mitochondrial Impairment in A Rat Model of Doxorubicin-Induced Cardiotoxicity

1. Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 339(13), 900-905. 2. Pacher, P., & Szabo, C. (2005). Role of peroxynitrite in the pathogenesis of cardiovascular disease. Cardiovascular Research, 68(1), 121-137. 3. Weiss, R. B. (1992). The anthracyclines: Will we ever find a better doxorubicin? Seminars in Oncology, 19(6), 670-686. 4. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185-229. 5. Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology & Therapeutics, 97(3), 227-244. 6. Monteiro, P., & Gonçalves, L. (2021). Cardiotoxicity of doxorubicin: From mitochondrial damage to cell death. Frontiers in Cardiovascular Medicine, 8, 631453. 7. Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy. Cardiology, 115(2), 155-162. 8. Fabbri, E., & Angeletti, S. (2018). Oxidative stress and mitochondrial dysfunction in doxorubicin cardiotoxicity. Antioxidants & Redox Signaling, 19(3), 165-178. 9. Doroshow, J. H. (1983). Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Research, 43(2), 460-472. 10. Murphy, M. P. (2009). How mitochondria produce reactive oxygen species. Biochemical Journal, 417(1), 1-13. 11. Neilan, T. G., & Jassal, D. S. (2015). Anthracycline cardiotoxicity: Basic and clinical perspectives. Heart, 101(11), 908-918. 12. Olson, R. D., & Mushlin, P. S. (1990). Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. The FASEB Journal, 4(13), 3076-3086. 13. Green, D. R., & Reed, J. C. (1998). Mitochondria and apoptosis. Science, 281(5381), 1309-1312. 14. Abraham, B. P., & Lyseng-Williamson, K. A. (2007). Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 67(13), 2043-2071. 15. Jones, R. L., & Swanton, C. (2012). Anthracyclines: Cardiovascular toxicity in cancer survivors. Clinical Oncology, 24(5), 311-322. 16. Octavia, Y., Tocchetti, C. G., & Gabrielson, K. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52(6), 1213-1225.17. Lenaz, G., & Genova, M. L. (2007). Structural and functional organization of the mitochondrial respiratory chain: A dynamic super-assembly. International Journal of Biochemistry & Cell Biology, 39(11), 1990-1999. 18. Keizer, H. G., & Pinedo, H. M. (1990). Doxorubicin (adriamycin) pharmacokinetics and metabolism. Cancer Treatment Reviews, 17(3), 233-243. 19. Zhang, S., Liu, X., & Bawa-Khalfe, T. (2012). Identification of the molecular mechanisms underlying doxorubicin-induced cardiotoxicity. Journal of Clinical Investigation, 122(7), 2814-2823. 20. Ayoub, S. S., Baxter, G. F., & Davidson, S. M. (2019). The role of mitochondria in doxorubicin-induced cardiotoxicity. Journal of Molecular and Cellular Cardiology, 129, 126-135. 21. Cadenas, E., & Davies, K. J. A. (2000). Mitochondrial free radical generation, oxidative stress, and aging. Free Radical Biology and Medicine, 29(3-4), 222-230. 22. Deng, S., & Yan, T. (2007). Mitochondrial dysfunction in doxorubicin-induced cardiomyopathy. Cell Research, 17(11), 940-941. 23. Conklin, K. A. (2004). Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies, 4(2), 110-130. 24. Wu, X., & Brewer, G. J. (2012). Redox imbalance and mitochondrial damage in the doxorubicin-induced cardiotoxicity model. PLoS ONE, 7(6), e41103. 25. Danz, E. D., Skramsted, J., Henry, N., Bennett, J. A., & Keller, R. S. (2009). Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the SIRT1 pathway. Free Radical Biology and Medicine, 46(12), 1589-1597. 26. Kang, Y. J. (2010). Antioxidant defenses and cardiac remodeling in doxorubicininduced cardiotoxicity. Cardiovascular Toxicology, 10(3), 165-176. 27. Ferreira, A. L., & Matsubara, L. S. (1997). Anthracycline-induced cardiotoxicity. Cardiovascular Research, 33(2), 372-383. 28. Hengstler, J. G., Fuchs, J., & Oesch, F. (1999). DNA strand breaks induced by doxorubicin via intercalation and iron-mediated free radical formation. Cancer Research, 59(2), 364-369. 29. Berthiaume, J. M., & Wallace, K. B. (2007). Persistent alterations to the gene expression profile of the heart following chronic doxorubicin treatment. Cardiovascular Toxicology, 7(3), 179-188. 30. Dobson, G. P., & Jones, M. W. (2004). Oxidative stress in heart failure and the role of antioxidants. Progress in Cardiovascular Diseases, 46(4), 288-305. 31. Murphy, M. P. (2009). How mitochondria produce reactive oxygen species. Biochemical Journal, 417(1), 1-13. 32. Arola, O. J., Saraste, A., Pulkki, K., Kallajoki, M., Parvinen, M., & Voipio-Pulkki, L. M. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Research, 60(7), 1789-1792. 33. Ewer, M. S., & Ewer, S. M. (2010). Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology, 7(10), 564-575. 34. Sawyer, D. B., Peng, X., Chen, B., & Pentassuglia, L. (2010). Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Progress in Cardiovascular Diseases, 53(2), 105-113. 35. Myers, C., & Bonow, R. (1992). Is anthracycline cardiotoxicity clinically relevant? Journal of Clinical Oncology, 10(8), 1746-1752.36. Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin. Cancer, 97(11), 2869-2879. 37. Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014). Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Medicinal Research Reviews, 34(1), 106-135.